转化生长因子-β配体陷阱(RAP-GRL)联合TMPRSS6反义寡核苷酸在纠正β-地中海贫血方面更优
本研究在非输血依赖型β-地中海贫血中间型小鼠中比较了RAP-GRL(鼠源luspatercept类似物)与TMPRSS6-ASO单药及联合的效果。结果显示RAP-GRL单药改善红细胞生成但对脾大和铁参数无或有限影响,TMPRSS6-ASO最有效改善红细胞指标、脾大和铁过载,结果为两者联合治疗β-地中海贫血提供临床前支持。
要点
- RAP-GRL单药改善红细胞生成,但对脾大和铁参数无或有限影响。
- TMPRSS6-ASO最有效改善红细胞指标、脾大和铁过载。
- 结果支持TMPRSS6-ASO与luspatercept联合治疗β-地中海贫血。
核心结论
- 临床前结果支持TMPRSS6-ASO与luspatercept联合治疗β-地中海贫血,两药联合有潜力同时改善红细胞和铁参数。
研究设计与样本
- 在非输血依赖型β-地中海贫血中间型小鼠中,使用鼠源luspatercept类似物RAP-GRL和TMPRSS6-ASO(IONIS TMPRSS6-LRx)进行治疗研究。
主要发现
- RAP-GRL单药改善红细胞生成,但对脾大和铁参数无或有限影响。
- TMPRSS6-ASO改善红细胞指标、改善脾大并最有效改善铁过载。
临床怎么用
- 作者认为这些结果提供临床前支持,支持将TMPRSS6-ASO与luspatercept联合用于治疗β-地中海贫血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A recently approved drug that induces erythroid cell maturation (luspatercept) has been shown to improve anemia and reduce the need for blood transfusion in non-transfusion-dependent as well as transfusion-dependent β-thalassemia (BT) patients. Although these results were predominantly positive, not all the patients showed the expected increase in hemoglobin (Hb) levels or transfusion burden reduction. Additional studies indicated that administration of luspatercept in transfusion-dependent BT was associated with increased erythropoietic markers, decreased hepcidin levels, and increased liver iron content. Altogether, these studies suggest that luspatercept may necessitate additional drugs for improved erythroid and iron management. As luspatercept does not appear to directly affect iron metabolism, we hypothesized that TMPRSS6-ASO could improve iron parameters and iron overload when co-administered with luspatercept. We used an agent analogous to murine luspatercept (RAP-GRL) and another novel therapeutic, IONIS TMPRSS6-LRx (TMPRSS6-ASO), a hepcidin inducer, to treat non-transfusion-dependent BT-intermedia mice. Our study shows that RAP-GRL alone improved red blood cell (RBC) production, with no or limited effect on splenomegaly and iron parameters. In contrast, TMPRSS6-ASO improved RBC measurements, ameliorated splenomegaly, and improved iron overload most effectively. Our results provide pre-clinical support for combining TMPRSS6-ASO and luspatercept in treating BT, as these drugs together show potential for simultaneously improving both erythroid and iron parameters in BT patients.
引用
- Guerra A, Hamilton N, Rivera A, et al. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia. Am J Hematol. 2024. PMID: 38659383. doi:10.1002/ajh.27332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。